Elevance Health Stock Plunges 5.27% on Lowered Earnings Outlook

On May 13, 2025, Elevance Health's stock experienced a significant drop of 5.27% in pre-market trading, indicating a notable shift in investor sentiment.

Analysts have revised their expectations for Elevance Health's second-quarter earnings, with K. Dey from Zacks Research now projecting earnings per share of $9.36, down from the previous estimate of $9.85. This adjustment reflects a more cautious outlook on the company's financial performance.

Elevance Health's stock is currently rated as a Zacks Rank 3, suggesting an inline return for investors. This rating is based on proprietary data and indicates a neutral stance on the stock's potential for growth.

For the year 2025, Elevance Health anticipates adjusted earnings per share from continuing operations to fall within the range of $4.85 to $5.10. This guidance provides a clearer picture of the company's expected financial performance for the year.